Yasir Mohamed, Lankala Chetan Reddy, Kalyankar Pravin, Ishak Angela, Mekhail Mario, Sestacovschi Cristina, Kima Elias
Division of Research, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Department of Internal Medicine, Uzhhorod National University, Uzhhorod, UKR.
Cureus. 2023 Aug 7;15(8):e43060. doi: 10.7759/cureus.43060. eCollection 2023 Aug.
Globally, the coronavirus disease 2019 (COVID-19) had a significant impact on everyone's lives and put a tremendous strain on healthcare systems. Since the outbreak began, remdesivir has been investigated as a potential treatment for COVID-19 that may be both effective and safe. Remdesivir has had a huge impact on the disease's progression, complications, and mortality. This review provides an updated assessment of the literature regarding remdesivir's efficacy and safety for the treatment of patients with COVID-19. The search was performed through PubMed, Web of Science, Cochrane, and Scopus for articles published from 2019 to September 20, 2022. Studies that assessed remdesivir's efficacy and safety were included in this review, with clinical improvements as the primary outcome measure. Seventeen studies were identified following the implementation of the search strategy. Among them, 11 corroborated remdesivir's efficacy. Meanwhile, the remaining six studies did not observe a statistically significant difference in clinical improvement. Remdesivir is a potentially safe and effective antiviral that shows clinical improvement especially when used during the early course of the disease. However, current literature still questions its safety in patients who are afflicted with the complications of COVID-19, highlighting the need for studies on a large scale.
在全球范围内,2019年冠状病毒病(COVID-19)对每个人的生活都产生了重大影响,并给医疗系统带来了巨大压力。自疫情爆发以来,瑞德西韦一直作为一种可能有效且安全的COVID-19潜在治疗方法进行研究。瑞德西韦对该疾病的进展、并发症和死亡率产生了巨大影响。本综述提供了关于瑞德西韦治疗COVID-19患者有效性和安全性的文献最新评估。通过PubMed、科学网、考克兰图书馆和Scopus检索了2019年至2022年9月20日发表的文章。本综述纳入了评估瑞德西韦有效性和安全性的研究,以临床改善作为主要结局指标。实施检索策略后共识别出17项研究。其中,11项证实了瑞德西韦的有效性。同时,其余6项研究未观察到临床改善方面的统计学显著差异。瑞德西韦是一种潜在安全有效的抗病毒药物,尤其在疾病早期使用时显示出临床改善。然而,当前文献仍对其在患有COVID-19并发症患者中的安全性提出质疑,凸显了大规模研究的必要性。